Lisa R Rodriguez

FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation

Reena Philip, Martha Donoghue, K. Goldberg, 2017, The oncologist.

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors

Reena Philip, L. Fashoyin-Aje, Martha Donoghue, 2021, Clinical Cancer Research.

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions

Jiang Liu, Reena Philip, R. Pazdur, 2020, Clinical Cancer Research.

FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.

K. Goldberg, R. Pazdur, M. Theoret, 2021, The oncologist.

FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma

Jiang Liu, L. Fashoyin-Aje, Martha Donoghue, 2020, Clinical Cancer Research.